Bolt Biotherapeutics (BOLT) Projected to Announce Earnings on Wednesday

Bolt Biotherapeutics (NASDAQ:BOLT) is expected to be issuing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($3.6850) per share and revenue of $0.45 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million.

Bolt Biotherapeutics Price Performance

BOLT stock opened at $6.45 on Wednesday. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61. Bolt Biotherapeutics has a one year low of $3.10 and a one year high of $7.78. The stock has a market cap of $12.44 million, a PE ratio of -0.39 and a beta of 0.85. The firm has a 50 day simple moving average of $4.25 and a two-hundred day simple moving average of $4.52.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $14.50.

Insider Buying and Selling at Bolt Biotherapeutics

In related news, CEO William Quinn sold 9,132 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the transaction, the chief executive officer directly owned 25,384 shares of the company’s stock, valued at approximately $82,244.16. This trade represents a 26.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 38,584 shares of company stock worth $128,361. Company insiders own 9.40% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.

Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.